CUE BIOPHARMA INC's ticker is CUE and the CUSIP is 22978P106. A total of 99 filers reported holding CUE BIOPHARMA INC in Q4 2020. The put-call ratio across all filers is 9.75 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,100,550 | -37.0% | 478,500 | 0.0% | 0.07% | -40.3% |
| Q2 2023 | $1,746,525 | +2.2% | 478,500 | 0.0% | 0.12% | -5.3% |
| Q1 2023 | $1,708,245 | +25.3% | 478,500 | 0.0% | 0.13% | -1.5% |
| Q4 2022 | $1,363,725 | +27.8% | 478,500 | 0.0% | 0.13% | +19.8% |
| Q3 2022 | $1,067,000 | -10.4% | 478,500 | 0.0% | 0.11% | -0.9% |
| Q2 2022 | $1,191,000 | -49.0% | 478,500 | 0.0% | 0.11% | -42.9% |
| Q1 2022 | $2,335,000 | -56.8% | 478,500 | 0.0% | 0.20% | -56.9% |
| Q4 2021 | $5,411,000 | -22.4% | 478,500 | 0.0% | 0.46% | -42.2% |
| Q3 2021 | $6,971,000 | +25.1% | 478,500 | 0.0% | 0.79% | +17.6% |
| Q2 2021 | $5,574,000 | -4.5% | 478,500 | 0.0% | 0.67% | -28.4% |
| Q1 2021 | $5,837,000 | -3.6% | 478,500 | -1.1% | 0.93% | -26.2% |
| Q4 2020 | $6,054,000 | -16.9% | 484,000 | 0.0% | 1.26% | -29.3% |
| Q3 2020 | $7,284,000 | – | 484,000 | – | 1.79% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Corriente Advisors, LLC | 1,915,219 | $23,959,000 | 5.70% |
| Prosight Management, LP | 906,569 | $11,341,000 | 5.24% |
| P.A.W. CAPITAL CORP | 140,000 | $1,751,000 | 1.54% |
| Voss Capital, LLC | 220,714 | $2,761,000 | 1.39% |
| Robertson Stephens Wealth Management, LLC | 484,000 | $6,054,000 | 1.26% |
| Slate Path Capital LP | 1,483,619 | $18,560,000 | 1.00% |
| Nantahala Capital Management | 2,506,772 | $31,360,000 | 0.97% |
| PRECEPT MANAGEMENT LLC | 150,000 | $1,877,000 | 0.76% |
| SANDERS MORRIS HARRIS LLC | 193,591 | $2,449,000 | 0.56% |
| Rock Creek Group, LP | 100,014 | $1,251,000 | 0.51% |